Marvel Biosciences (MRVL) Stock Overview
A biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
MRVL Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Marvel Biosciences Corp. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.16 |
| 52 Week High | CA$0.40 |
| 52 Week Low | CA$0.075 |
| Beta | 0.63 |
| 1 Month Change | 3.23% |
| 3 Month Change | 18.52% |
| 1 Year Change | 60.00% |
| 3 Year Change | 68.42% |
| 5 Year Change | n/a |
| Change since IPO | -58.97% |
Recent News & Updates
Recent updates
Shareholder Returns
| MRVL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | -3.0% | 5.6% | 1.3% |
| 1Y | 60.0% | 27.2% | 41.6% |
Return vs Industry: MRVL exceeded the Canadian Biotechs industry which returned 27.2% over the past year.
Return vs Market: MRVL exceeded the Canadian Market which returned 41.6% over the past year.
Price Volatility
| MRVL volatility | |
|---|---|
| MRVL Average Weekly Movement | 14.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 10.9% |
| 10% most volatile stocks in CA Market | 18.9% |
| 10% least volatile stocks in CA Market | 3.9% |
Stable Share Price: MRVL's share price has been volatile over the past 3 months compared to the Canadian market.
Volatility Over Time: MRVL's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Canadian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | Rod Matheson | marvelbiotechnology.com |
Marvel Biosciences Corp., a biotechnology company, develops synthetic chemical derivatives of the original approved drug for the new disease indication in Canada. The company’s lead compound MB-204, a novel fluorinated derivative of istradefylline, an adenosine A2a receptor antagonist to treat alzheimer’s disease and autism spectrum disorder, as well as depression and anxiety. It provides non-hallucinogenic neuroplasticity program.
Marvel Biosciences Corp. Fundamentals Summary
| MRVL fundamental statistics | |
|---|---|
| Market cap | CA$10.71m |
| Earnings (TTM) | -CA$2.09m |
| Revenue (TTM) | n/a |
Is MRVL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MRVL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$2.09m |
| Earnings | -CA$2.09m |
Last Reported Earnings
Jan 31, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.033 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -59.9% |
How did MRVL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/20 02:29 |
| End of Day Share Price | 2026/04/20 00:00 |
| Earnings | 2026/01/31 |
| Annual Earnings | 2025/07/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Marvel Biosciences Corp. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.